DeepHealth vs ScreenPoint Transpara

ScreenPoint says Transpara was the software in the MASAI randomized screening trial, run by Lund University in Sweden. ScreenPoint reports a 12% lower interval cancer rate and sensitivity of 80.5% with AI support against 73.8% with standard double reading, at 98.5% specificity, across more than 105,000 women. The setting was Swedish double reading, so how well it carries to a US single-reader workflow is open. Screening programs running double reading are Transpara's natural fit, with 2D and 3D mammogram support and eight 510(k)s, the latest in August 2026. US outpatient breast imaging groups lean to DeepHealth, whose Saige-Dx, Saige-Density and breast arterial calcification products sit inside RadNet. Its Saige-Dx evidence is a retrospective, enriched set of 240 cases read by 18 readers, and the authors work for DeepHealth. A screening program choosing on randomized evidence gets MASAI only from Transpara, so DeepHealth falls off that list.